Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $8.80, but opened at $8.48. Pharming Group shares last traded at $8.49, with a volume of 1,667 shares trading hands.
Analysts Set New Price Targets
A number of research firms have recently weighed in on PHAR. HC Wainwright reiterated a "buy" rating and set a $37.00 target price on shares of Pharming Group in a report on Tuesday. Jefferies Financial Group started coverage on shares of Pharming Group in a report on Monday, December 9th. They issued a "buy" rating and a $14.00 price target on the stock. Finally, Oppenheimer decreased their price objective on shares of Pharming Group from $31.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, October 28th.
Get Our Latest Research Report on PHAR
Pharming Group Price Performance
The stock has a market cap of $575.92 million, a PE ratio of -32.65 and a beta of 0.05. The business has a fifty day simple moving average of $8.28 and a two-hundred day simple moving average of $8.13. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.
Institutional Investors Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,110 shares of the company's stock after buying an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 as of its most recent SEC filing. Institutional investors own 0.03% of the company's stock.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
